PT  - JOURNAL ARTICLE
AU  - Perkins, Douglas J
AU  - Villescas, Steven
AU  - Wu, Terry H.
AU  - Muller, Timothy
AU  - Bradfute, Steven
AU  - Hurwitz, Ivy
AU  - Cheng, Qiuying
AU  - Wilcox, Hannah
AU  - Weiss, Myissa
AU  - Bartlett, Chris
AU  - Langsjoen, Jens
AU  - Seidenberg, Phil
TI  - COVID-19 Global Pandemic Planning: Decontamination and Reuse Processes for N95 Respirators
AID  - 10.1101/2020.04.09.20060129
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.09.20060129
4099  - http://medrxiv.org/content/early/2020/04/14/2020.04.09.20060129.short
4100  - http://medrxiv.org/content/early/2020/04/14/2020.04.09.20060129.full
AB  - Coronavirus disease 2019 (COVID-19) is an illness caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease was first identified as a cluster of respiratory illness in Wuhan City, Hubei Province, China in December 2019, and has rapidly spread across the globe to greater than 200 countries. Healthcare providers are at an increased risk for contracting the disease due to occupational exposure and require appropriate personal protective equipment (PPE), including N95 respirators. The rapid worldwide spread of high numbers of COVID-19 cases has facilitated the need for a substantial supply of PPE that is largely unavailable in many settings, thereby creating critical shortages. Creative solutions for the decontamination and safe reuse of PPE to protect our frontline healthcare personnel are essential. Here, we describe the development of a process that began in late February 2020 for selecting and implementing the use of hydrogen peroxide vapor (HPV) as viable method to reprocess N95 respirators. Since pre-existing HPV decontamination chambers were not available, we optimized the sterilization process in an operating room after experiencing initial challenges in other environments. Details are provided about the prioritization and implementation of processes for collection and storage, pre-processing, HPV decontamination, and post-processing of filtering facepiece respirators (FFRs). Important lessons learned from this experience include, developing an adequate reserve of PPE for effective reprocessing and distribution, and identifying a suitable location with optimal environmental controls (i.e., operating room). Collectively, information presented here provides a framework for other institutions considering decontamination procedures for N95 respirators.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunds for the work where supported by the Center for Global Health, Department of Internal Medicine.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data will be made available.